11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Atacicept: Ph IIb ADDRESS II data

The double-blind, international Phase IIb ADDRESS II trial in 306 SLE patients receiving standard of care (SOC) showed that once-weekly 75 and 150 mg subcutaneous atacicept each missed the primary endpoint of a greater proportion...
07:00 , Sep 18, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Chris Cain, Associate Editor, and Kai-Jye Lou, Senior Writer RNA sequencing standardized The FDA has convened a consortium to review the status of RNA sequencing for drug development and outline hurdles for incorporating the technology into the...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Merck KGaA, Feinstein Institute deal

Merck's Merck Serono S.A. subsidiary partnered with the institute to develop antibodies to treat systemic lupus erythematosus (SLE). Merck Serono will fund a research program at the institute on antibodies that inhibit proteins responsible...
07:00 , Jul 2, 2012 |  BioCentury  |  Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc., starting with several new hires, including a CSO from...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc., the outcome hardly looked like a slam dunk. Based on a pair of...
07:00 , Oct 4, 2010 |  BioCentury  |  Strategy

Times changed

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...
07:00 , Oct 12, 2009 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 10/9 cls Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Jefferies Eun Yang Price target Buy 1% $44.66 Yang raised her target to $49 from $42. She...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

Atacicept: Phase II discontinued

Zymogenetics disclosed in an SEC filing that partner Merck Serono S.A. discontinued ongoing studies for atacicept to treat MS. Merck made the decision after an Independent DMC "determined that the risk/benefit relationship did not...
07:00 , Oct 5, 2009 |  BioCentury  |  Finance

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...